Showing 6161-6170 of 7756 results for "".
- Calling All Dermatologists: The Sun Heroes Initiative Wants You to Become a Herohttps://practicaldermatology.com/news/calling-all-dermatologists-the-sun-heroes-initiative-wants-you-to-help-bring-sun-safety-programs-to-elementary-schools/2461232/CeraVe and L'Oreal Dermatological Beauty brand La Roche-Posay are teaming up with dermatologist Amy Brodsky, MD to bring sun safety programs to elementary schools around the country. Sun Heroes is an educational program that equips healthcare professionals with
- FDA Approves Olumiant from Eli Lilly for Alopecia Areatahttps://practicaldermatology.com/news/fda-approves-olumiant-from-eli-lilly-for-alopecia-areata/2461231/Olumiant (baricitinib) from Eli Lilly and Company is approved to treat adult patients with severe alopecia areata. FDA action marks the first approval of a systemic treatment for alopecia areata. Olumiant is
- Higher Fish Consumption Linked to Melanoma Riskhttps://practicaldermatology.com/news/higher-fish-consumption-linked-to-melanoma-risk/2461229/Eating higher levels of fish, including tuna and non-fried fish, may increase melanoma risk, according to a large study of US adults published in Cancer Causes & Control. When compared to those whose median daily fish intake was 3.2 grams, the risk of malignant melanom
- New Research Reveals Roughly 4 in 5 Acne Sufferers Have Missed Moments in Their Life Due to Acnehttps://practicaldermatology.com/news/new-research-reveals-roughly-4-in-5-acne-sufferers-have-missed-moments-in-their-life-due-to-acne/2461227/Ninety percent of moderate to severe acne sufferers said having acne-free skin would dramatically change the way they live their life, according to a new survey released today. The survey was conducted on behalf of Cutera, Inc., which offers AviClear, the first
- FDA Approves Dupixent for Children 6 Months to 5 Years with Moderate to Severe Atopic Dermatitishttps://practicaldermatology.com/news/fda-approves-dupixent-for-children-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis/2461224/The FDA has approved Regeneron Pharmaceuticals, Inc. and Sanofi's Dupixent (dupilumab) for children aged 6 months to 5 years with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Regu
- June 2022 Marks Scleroderma Awareness Monthhttps://practicaldermatology.com/news/june-2022-marks-scleroderma-awareness-month/2461222/June is Scleroderma Awareness Month, and "Know Scleroderma" is the National Scleroderma Foundation's theme for 2022. Throughout the month, the Foundation will post videos and photos of individuals affected by scleroderma on its
- Message from ASLMS President Dr. Paul M. Friedmanhttps://practicaldermatology.com/news/message-from-aslms-president-dr-paul-m-friedman/2461221/Dr. Paul M. Friedman, president of the American Society for Laser Medicine and Surgery (ASLMS), is calling on members to expand philanthropic programs that can help change lives with lasers. “In the coming year, I will be looking to the membership to bring their talents forwa
- Cynosure Upgrades PicoSure System with PicoSure Pro Devicehttps://practicaldermatology.com/news/cynosure-upgrades-picosure-system-with-picosure-pro-device/2461220/Cynosure is launching the PicoSure Pro device, the latest upgrade to the company's PicoSure system. An FDA-cleared 755nm picosecond laser, the PicoSure Pro device uniquely delivers energy in a trillionth of a second, utilizing pressure instead of heat to provide safe and effec
- FDA Accepts sBLA for Priority Review for Dupixent in PNhttps://practicaldermatology.com/news/fda-accepts-sbla-for-priority-review-for-dupixent-in-pn/2461218/FDA has accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) from Sanofi and Regeneron to treat adults with prurigo nodularis. The target action date for the FDA decision is September 30, 2022. The sBLA is supported by dat
- Apyx Medical Corporation Receives FDA 510(k) Clearance for Renuvion Handpiecehttps://practicaldermatology.com/news/apyx-medical-corporation-receives-fda-510k-clearance-for-renuvion-handpiece/2461216/The U.S. Food and Drug Administration has granted marketing clearance to Apyx Medical Corporation’s Renuvion Dermal Handpiece for specific dermal resurfacing procedures. The Renuvion Dermal Handpiece is indicated for dermatological procedures for the treatment of moderate to